One Slide, 15,000 Signals
Ataraxis AI says its NEO model predicts response to neoadjuvant therapy for breast cancer from a routine biopsy slide by estimating expression of nearly 15,000 genes. The company reports results across 1,412 patients in diverse real-world cohorts and two clinical trials.
Ataraxis AI says its NEO model predicts response to neoadjuvant therapy for breast cancer from a routine biopsy slide by estimating expression of nearly 15,000 genes. The company reports results across 1,412 patients in diverse real-world cohorts and two clinical trials.
Ataraxis AI published the report on October 4, 2026.
Ataraxis AI reports that its NEO model predicted breast-cancer response to neoadjuvant therapy from a routine biopsy slide by estimating expression of nearly 15,000 genes. The report covers 1,412 patients across real-world cohorts and two clinical trials. How could AI-generated biological signals support more personalized treatment decisions? martinezaistudios.com